Table 2.

Effect of cinacalcet treatment on serum AP in cinacalcet-treated patients and control subjects: Increased likelihood of achieving a ≥20% reduction in serum APa

Assessment PointbCinacalcet-Treated Patients (n [%])Control Subjects (n [%])Adjusted RP (95% CI) of AP Reduction: Cinacalcet versus Placeboc
Week 12/16 (n = 890)
    assessable patients (n)507383
    patients with any reduction in AP from baseline (n [%])230 (45.4)155 (40.5)1.09 (0.94 to 1.27)
    patients with a ≥20% reduction in AP from baseline (n [%])99 (19.5)36 (9.4)1.92 (1.35 to 2.75)
Week 26 (n = 793)
    assessable patients (n)446347
    patients with any reduction in AP from baseline (n [%])254 (56.9)137 (39.5)1.44 (1.24 to 1.68)
    patients with a ≥20% reduction in AP from baseline (n [%])134 (30.0)58 (16.7)1.73 (1.32 to 2.26)
Week 42 (n = 219)
    assessable patients (n)104115
    patients with any reduction in AP from baseline (n [%])64 (61.5)45 (39.1)1.63 (1.27 to 2.08)
    patients with a ≥20% reduction in AP from baseline (n [%])38 (36.5)17 (14.8)2.61 (1.64 to 4.14)
Week 52 (n = 205)
    assessable patients (n)98107
    patients with any reduction in AP from baseline (n [%])57 (58.2)38 (35.5)1.74 (1.31 to 2.31)
    patients with a ≥20% reduction in AP from baseline (n [%])38 (38.8)19 (17.8)2.33 (1.50 to 3.61)
  • a CI, confidence interval; RP, relative proportion.

  • b n is the number of assessable patients at each assessment point.

  • c Adjusted for age, gender, race, BMI, dialysis vintage, baseline AP history of diabetes, and history of cardiovascular disease (including cerebrovascular accident, peripheral vascular disease, myocardial infarction, coronary artery disease, and congestive heart failure) and stroke.